EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MTHFR and MTRR Polymorphisms Predict Sex-Dependent Psychotic Symptom Improvements, Not Metabolic Changes

Sergej Nadalin, Ivan Majdandžić, Jadranka Vraneković iD, Vjekoslav Peitl iD, Maja Vilibić iD, Ante Silić, Dalibor Karlović iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Sergej Nadalin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, General Hospital "Dr. Josip Benčević", 35000 Slavonski Brod, Croatia. Hauptthemen laut MEDLINE: Methylenetetrahydrofolate Reductase (NADPH2), Ferredoxin-NADP Reductase, Polymorphism, Single Nucleotide, Psychotic Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Rijeka, University of Rijeka, Croatia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated whether antipsychotic treatment response was influenced by the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase (MTHFR), and A66G of methyltetrahydrofolate–homocysteine methyltransferase reductase (MTRR)—genes central to folate and homocysteine metabolism and methylation, pathways often altered in schizophrenia patients. To our knowledge, no study has examined associations of C677T and A1298C with changes in schizophrenia symptom severity after antipsychotic treatment, while studies on metabolic outcomes remain sparse and inconsistent. The MTRR A66G has been assessed only once for metabolic parameters—not symptom severity—and sex-stratified analyses are lacking for all polymorphisms. A total of 186 antipsychotic-naïve first-episode or nonadherent chronic psychosis patients and 242 controls were genotyped using PCR-RFLP. Clinical assessments—including Positive and Negative Syndrome Scale (PANSS) scores, PANSS factor scores, and metabolic parameters (fasting plasma lipids and glucose levels, and body mass index)—were conducted at baseline and after 8 weeks. Genotype and allele frequencies did not differ between patients and controls. Significant associations emerged only for symptom changes, specifically within PANSS factor domains, in a sex-dependent manner. Female MTHFR 1298-A allele carriers (AA and AC) showed greater improvement in PANSS negative factor scores, whereas male MTRR 66-G allele carriers (GG and AG) showed reduced improvement in PANSS cognitive factor scores. Effect sizes were strong to very strong, with relatively modest contributions. MTHFR A1298C and MTRR A66G have sex-dependent impacts on symptomatic improvement—but not metabolic outcomes—after antipsychotic treatment. Accordingly, folate–homocysteine genetic markers and sex-specific factors can guide the development of personalized antipsychotic treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methylenetetrahydrofolate Reductase (NADPH2)Ferredoxin-NADP ReductasePolymorphism, Single NucleotidePsychotic DisordersSchizophreniaHumansMaleFemaleAdultAntipsychotic AgentsGene FrequencySex FactorsGenotype

Stichwörter der Autor:innen

DNA methylationantipsychotic agentsfolic acidhomocysteinemetabolismmethylenetetrahydrofolate reductase (MTHFR)methyltetrahydrofolate–homocysteine methyltransferase reductase (MTRR)pharmacogeneticspolymorphism, geneticpsychotic disorderssex factors

Substanzen

Methylenetetrahydrofolate Reductase (NADPH2)methionine synthase reductaseFerredoxin-NADP ReductaseMTHFR protein, humanAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, General Hospital "Dr. Josip Benčević", 35000 Slavonski Brod, Croatia.
  • School of Medicine, Catholic University of Croatia, 10000 Zagreb, Croatia.
  • Department of Anesthesiology, Reanimatology and Intensive Care Medicine, General Hospital "Dr. Josip Benčević", 35000 Slavonski Brod, Croatia.
  • Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
  • Department of Psychiatry, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia.

ORCID-Profile: Jadranka Vraneković, Vjekoslav Peitl, Maja Vilibić, Dalibor Karlović

Förderung

  • University of Rijeka
  • University of Rijeka, Croatia

Zitieren

APA

Nadalin, S., Majdandžić, I., Vraneković, J., Peitl, V., Vilibić, M., Silić, A., & Karlović, D. (2026). MTHFR and MTRR Polymorphisms Predict Sex-Dependent Psychotic Symptom Improvements, Not Metabolic Changes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031348

Vancouver

Nadalin S, Majdandžić I, Vraneković J, Peitl V, Vilibić M, Silić A, et al. MTHFR and MTRR Polymorphisms Predict Sex-Dependent Psychotic Symptom Improvements, Not Metabolic Changes. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031348

BibTeX
@article{Nadalin2026,
  author = {Nadalin, Sergej and Majdandžić, Ivan and Vraneković, Jadranka and Peitl, Vjekoslav and Vilibić, Maja and Silić, Ante and Karlović, Dalibor},
  title = {MTHFR and MTRR Polymorphisms Predict Sex-Dependent Psychotic Symptom Improvements, Not Metabolic Changes},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031348}
}
Kostenlos starten →